
Dishman Carbogen Amcis (DCAL) 52 Week Low Streak: Why DCAL Keeps Trading Near Its Yearly Low
Updated: 20 Nov 2026 • 9:41 am
Posted by:

Dishman Carbogen Amcis Ltd. (DCAL) has now traded within 2% of its 52-week low for its second straight session, with the cumulative move across this streak at -3.75%. At 9:23 AM IST, the stock was trading at Rs 116.7 after touching a low of Rs 115.2. The latest Univest data confirms the repeated-low pattern, but it does not establish a company-specific cause for the continued weakness.
Compared with the previous close of Rs 118.6, DCAL was down Rs 1.9, or 1.6%, and moved between Rs 115.2 and Rs 118.5 during the morning session. The opening price was Rs 115.2, which also marked the day’s low, while the current price sat near the upper end of the intraday range. With a market capitalisation of Rs 1,901 crore, the repeated-low pattern is more meaningful than a single-day slip because it shows that the stock has stayed near its yearly low across multiple sessions, rather than only briefly drifting lower.
Dishman Carbogen Amcis 52 Week Low Streak: Consecutive Low Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 116.7 |
| Previous Close | Rs 118.6 |
| Today's Move | Rs -1.9 (-1.6%) |
| Open | Rs 115.2 |
| High | Rs 118.5 |
| Low | Rs 115.2 |
| Market Capitalisation | Rs 1,901 crore |
Dishman Carbogen Amcis Ltd. (DCAL) traded at Rs 116.7 versus the previous close of Rs 118.6, a fall of 1.6%. The stock opened at Rs 115.2, reached a high of Rs 118.5, touched a low of Rs 115.2.
Dishman Carbogen Amcis share price today stayed under pressure as DCAL traded at Rs 116.7, below the previous close of Rs 118.6. That left the stock down Rs 1.9, or 1.6%, in morning trade. The day opened at Rs 115.2 and touched a high of Rs 118.5, while the low was also Rs 115.2, placing the current price closer to the upper end of the intraday band. For readers tracking Dishman Carbogen Amcis share price today, the key takeaway is not just the smaller intraday move, but the fact that the stock remains near its 52-week low for a second straight session. The market capitalisation stood at Rs 1,901 crore, which places the company in the broader mid-sized bracket by value, even as the share price continues to reflect persistent weakness. In the context of Dishman Carbogen Amcis stock news, the latest price action keeps the focus on repeated downside rather than any sign of a turnaround.
What The Repeated 52-Week Lows Show
DCAL has now stayed within 2% of its 52-week low for the second straight session, and that pattern matters more than a one-session move. The cumulative decline across the streak is -3.75%, which tells investors that the weakness has been sustained rather than isolated. This is the core distinction in a Dishman Carbogen Amcis 52 Week Low Streak story: the stock is not simply reacting to one trading day, but continuing to hover near its one-year low across consecutive sessions.
At this stage, the latest Univest data confirms the pattern, but it does not identify a company-specific trigger. That means the market can observe the repeated low-price behaviour, yet should avoid reading a precise cause into it without additional disclosure. For anyone following Stocks Hitting 52 Week Lows, this kind of setup often deserves more attention than a single print because it signals that the stock price has remained weak through more than one trading session. In practical terms, the Dishman Carbogen Amcis 52 Week Low Streak keeps the focus on persistence, not just intensity, of the downside.
Dishman Carbogen Amcis Ltd. (DCAL) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,901 crore |
| P/E Ratio | 16.48x |
| P/B Ratio | 0.28x |
| ROE | 1.56% |
| ROCE | 3.21% |
| EPS | Rs -7.39 |
| Book Value Per Share | Rs 425.5 |
| Dividend Yield | 0% |
Dishman Carbogen Amcis Ltd. (DCAL) fundamental metrics show P/E 16.48x, P/B 0.28x, ROE 1.56%, ROCE 3.21%. These figures provide context only and are not a buy or sell signal.
Dishman Carbogen Amcis Ltd. has a market capitalisation of Rs 1,901 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 16.48x, P/B at 0.28x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 1.56% and ROCE of 3.21%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs -7.39, book value per share of Rs 425.5, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 26.6x, median ROE of 11.22%, median ROCE of 13.1%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 16.48x |
| Benchmark Median P/E | 26.6x |
| Benchmark Average P/E | 51.31x |
| Benchmark P/E Range | 0x to 1,399.41x |
| Company P/B Ratio | 0.28x |
| Benchmark Median P/B | 2.84x |
| Company ROE | 1.56% |
| Benchmark Median ROE | 11.22% |
| Company ROCE | 3.21% |
| Benchmark Median ROCE | 13.1% |
| Company Market Capitalisation | Rs 1,901 crore |
| Benchmark Median Market Cap | Rs 742.37 crore |
Dishman Carbogen Amcis Ltd. (DCAL) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Dishman Carbogen Amcis Ltd. (DCAL) has a P/E ratio of 16.48x, which is below the benchmark median of 26.6x, a difference of -38.05%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Dishman Carbogen Amcis Ltd. (DCAL) has a ROE of 1.56%, which is below the benchmark median of 11.22%, a difference of -86.1%. Dishman Carbogen Amcis Ltd. (DCAL) has a ROCE of 3.21%, which is below the benchmark median of 13.1%, a difference of -75.5%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Venus Remedies Ltd. | VENUSREM | 1,937.28 | 16.48 | 2.85 | 16.79 | 21.88 |
| Hester Biosciences Ltd. | HESTERBIO | 1,984.91 | 14.05 | 4.27 | 17.05 | 16.21 |
| Beta Drugs Ltd. | BETA | 2,004.38 | 37.79 | 4.48 | 18.78 | 19.16 |
| Windlas Biotech Ltd. | WINDLAS | 2,040.1 | 30.46 | 3.61 | 12.52 | 16.06 |
| NGL Fine-Chem Ltd. | NGLFINE | 1,763.49 | 26.97 | 4.75 | 15.74 | 16.88 |
Dishman Carbogen Amcis Ltd. (DCAL) has a P/E ratio of 16.48x compared with the displayed peer median of 26.97x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 1.56% compares with a peer median of 16.79% across the companies shown in the table. ROCE stood at 3.21% versus the displayed peer median of 16.88%, providing a capital-efficiency comparison. Dishman Carbogen Amcis Ltd. (DCAL) has a market capitalisation of Rs 1,901 crore. Among the 5 peers shown, 4 have a larger market capitalisation.
Why Investors Are Watching
- DCAL is in a second straight session of trading within 2% of its 52-week low, keeping the focus on repeated weakness rather than a one-day move.
- The cumulative streak move of -3.75% shows that the downside has persisted across sessions.
- The stock’s P/B of 0.28 is far below the healthcare peer median, but profitability remains weak.
- ROE of 1.56% and ROCE of 3.21% are well under the industry medians, which matters for Dishman Carbogen Amcis Fundamental Analysis.
- Investors tracking DCAL Share Price Today may watch whether the stock stays near the yearly low or begins to move away from that range.
About The Company
Dishman Carbogen Amcis Ltd. is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. The company has a market capitalisation of Rs 1,901 crore and is followed by investors for its share price behaviour, valuation profile and operating performance. In the current phase, the most relevant numbers are the low P/B, the subdued return ratios and the repeated near-low trading pattern. That combination makes Dishman Carbogen Amcis Company News and Dishman Carbogen Amcis Share Price Update relevant for readers who want to understand the stock beyond a single intraday move.
For market participants, the key question is not whether the stock has had one weak print, but whether the Dishman Carbogen Amcis 52 Week Low Streak continues or starts to ease. The company’s industry context, valuation ratios and earnings profile will remain central to that assessment.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
What does a Dishman Carbogen Amcis 52 Week Low Streak mean?
Ans. It means DCAL has traded within 2% of its 52-week low for multiple consecutive sessions. In this case, the stock has done so for its second straight session, which shows repeated weakness rather than a one-off move.
How much has DCAL moved across this streak?
Ans. The cumulative move across the streak is -3.75%. That figure reflects the repeated near-low trading pattern over the two sessions and is more useful than looking at only one day’s price change.
Is there a company-specific reason for the latest fall?
Ans. The latest Univest data confirms the repeated-low pattern, but it does not establish a company-specific cause. Investors should treat the move as a verified price pattern unless and until fresh company or market disclosure explains it.
How did Dishman Carbogen Amcis trade today?
Ans. DCAL was trading at Rs 116.7 after opening at Rs 115.2 and touching a high of Rs 118.5. The previous close was Rs 118.6, so the stock was down Rs 1.9, or 1.6%, in morning trade.
Is Dishman Carbogen Amcis cheap on valuation?
Ans. The stock trades at a P/E of 16.48 and a P/B of 0.28, which is below the healthcare peer median on both measures. However, the weak ROE and ROCE mean investors should read valuation together with profitability, not in isolation.
How does DCAL compare with healthcare peers?
Ans. DCAL’s valuation is lower than many peers, but its return ratios are also much weaker. Several peer companies in the same industry have stronger ROE and ROCE, which helps explain why they trade at higher multiples.
What should investors monitor next?
Ans. Investors can watch whether the stock continues to trade near its one-year low or starts moving away from that band. They should also track company financial performance, profitability trends and any fresh stock-specific disclosure.
Why is the Dishman Carbogen Amcis 52 Week Low Streak important for readers?
Ans. It highlights a multi-session pattern, not just a single weak price point. For readers following Dishman Carbogen Amcis 52 Week Low Streak updates, that distinction helps separate a brief move from a more persistent decline story.
Track Dishman Carbogen Amcis Ltd. (DCAL) Share Price on Univest
Use Dishman Carbogen Amcis Ltd. (DCAL) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Recent Articles

Medi Assist Healthcare Services (MEDIASSIST) Share Price hits fresh 52-week low at Rs 261.85
20 November 2026

Ultratech Cement (ULTRACEMCO) Share Price near 52-week high as stock trades at Rs 12,730
20 November 2026

Gujarat Fluorochemicals (FLUOROCHEM) Share Price Hits Fresh 52-Week High as FLUOROCHEM Traded at Rs 4,951
20 November 2026

Coforge Ltd. (COFORGE) Share Price Near 52-Week High as Stock Trades at Rs 2,088
20 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Medi Assist Healthcare Services (MEDIASSIST) Share Price hits fresh 52-week low at Rs 261.85
Ultratech Cement (ULTRACEMCO) Share Price near 52-week high as stock trades at Rs 12,730
Gujarat Fluorochemicals (FLUOROCHEM) Share Price Hits Fresh 52-Week High as FLUOROCHEM Traded at Rs 4,951
Coforge Ltd. (COFORGE) Share Price Near 52-Week High as Stock Trades at Rs 2,088
Hyundai Motor India Ltd. (HYUNDAI) Share Price Rise Streak Continues in Second Straight Session

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





